Literature DB >> 22939035

Implantable cardiac defibrillators and sudden death in recent onset nonischemic cardiomyopathy: results from IMAC2.

Richard Sheppard1, Paul J Mather, Jeffrey D Alexis, Randall C Starling, John P Boehmer, Vinay Thohan, Daniel F Pauly, David W Markham, Mark Zucker, Kevin E Kip, Dennis M McNamara.   

Abstract

BACKGROUND: Given the potential for recovery in recent onset nonischemic cardiomyopathy (ROCM), the timing and need for implantable cardioverter-defibrillator (ICDs) remains controversial. We examined the utilization of ICDs and the impact on survival for subjects with ROCM. METHODS AND
RESULTS: An National Heart, Lung, and Blood Institute sponsored registry enrolled 373 subjects with ROCM, all with a left ventricular ejection fraction (LVEF) ≤0.40 and ≤6 months of symptoms. The mean age was 45 ± 14 years, 38% were female, 21% black, 75% New York Heart Association II/III, and the mean LVEF was 0.24 ± 0.08. Survival was comparable for subjects with an ICD within 1 month of entry (n = 43, 1/2/3 year % survival = 97/97/92) and those with no ICD at 1 month (n = 330, % survival = 98/97/95, P = .30) and between those with and without an ICD at 6 months (ICD, n = 73, 1/2/3 year % survival = 98/98/95; no ICD, n = 300, % survival = 98/96/95, P = .95). There were only 6 sudden cardiac deaths (SCD) noted (% survival free from SCD = 99/98/97) and these occurred in 1.9% of subjects without ICD and 0.9% of those with a device (P = .50).
CONCLUSIONS: In a multicenter cohort of ROCM the risk of SCD was low at 1% per year. Early ICD placement did not impact survival and can be deferred while assessing potential for myocardial recovery.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22939035      PMCID: PMC6481679          DOI: 10.1016/j.cardfail.2012.07.004

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  10 in total

1.  Prevalence and outcomes of patients receiving implantable cardioverter-defibrillators for primary prevention not based on guidelines.

Authors:  Yehoshua C Levine; Mark K Tuttle; Michael A Rosenberg; Randal Goldberg; Jason Matos; Michelle Samuel; Daniel B Kramer; Alfred E Buxton
Journal:  Am J Cardiol       Date:  2015-03-12       Impact factor: 2.778

Review 2.  [The wearable cardioverter/defibrillator : Temporary protection from sudden cardiac death].

Authors:  D Duncker; J Bauersachs; C Veltmann
Journal:  Internist (Berl)       Date:  2016-09       Impact factor: 0.743

3.  Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the PROLONG study.

Authors:  David Duncker; Thorben König; Stephan Hohmann; Johann Bauersachs; Christian Veltmann
Journal:  Clin Cardiol       Date:  2017-03-23       Impact factor: 2.882

Review 4.  The Wearable Cardioverter/Defibrillator - Toy Or Tool?

Authors:  David Duncker; Christian Veltmann
Journal:  J Atr Fibrillation       Date:  2016-04-30

Review 5.  [Wearable defibrillator : Current evidence].

Authors:  David Duncker; Christian Veltmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-10-24

6.  Comparison of the Outcome of Patients Protected by the Wearable Cardioverter Defibrillator (WCD) for <90 Wear Days versus ≥90 Wear Days.

Authors:  Tobias C Dreher; Ibrahim El-Battrawy; Susanne RÖger; Stephanie L Rosenkaimer; Stefan Gerhards; JÜrgen Kuschyk; Martin Borggrefe; Ibrahim Akin
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

7.  Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.

Authors:  David Duncker; Thorben König; Stephan Hohmann; Johann Bauersachs; Christian Veltmann
Journal:  J Am Heart Assoc       Date:  2017-01-17       Impact factor: 5.501

8.  Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.

Authors:  Susanne Röger; Stefanie L Rosenkaimer; Anna Hohneck; Siegfried Lang; Ibrahim El-Battrawy; Boris Rudic; Erol Tülümen; Ksenija Stach; Jürgen Kuschyk; Ibrahim Akin; Martin Borggrefe
Journal:  BMC Cardiovasc Disord       Date:  2018-03-15       Impact factor: 2.298

Review 9.  Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure.

Authors:  David Duncker; Christian Veltmann
Journal:  Curr Heart Fail Rep       Date:  2018-12

Review 10.  Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.

Authors:  Carsten Tschöpe; Enrico Ammirati; Biykem Bozkurt; Alida L P Caforio; Leslie T Cooper; Stephan B Felix; Joshua M Hare; Bettina Heidecker; Stephane Heymans; Norbert Hübner; Sebastian Kelle; Karin Klingel; Henrike Maatz; Abdul S Parwani; Frank Spillmann; Randall C Starling; Hiroyuki Tsutsui; Petar Seferovic; Sophie Van Linthout
Journal:  Nat Rev Cardiol       Date:  2020-10-12       Impact factor: 49.421

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.